WO2025056929 - SEALED SINGLE-DOSE CONTAINER OF LEVOTHYROXINE AQUEOUS SOLUTION SUITABLE FOR ORAL ADMINISTRATION
National phase entry:
Publication Number
WO/2025/056929
Publication Date
20.03.2025
International Application No.
PCT/GR2024/000027
International Filing Date
13.09.2024
Title **
[English]
SEALED SINGLE-DOSE CONTAINER OF LEVOTHYROXINE AQUEOUS SOLUTION SUITABLE FOR ORAL ADMINISTRATION
[French]
RÉCIPIENT UNIDOSE SCELLÉ DE SOLUTION AQUEUSE DE LÉVOTHYROXINE APPROPRIÉE POUR UNE ADMINISTRATION ORALE
Applicants **
TSETI, Ioulia
Inventors
TSETI, Ioulia
Priority Data
20230100740
15.09.2023
GR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1879 | |
| EPO | Filing, Examination, Granting | 6289 | |
| Japan | Filing, Examination, Granting | 2007 | |
| South Korea | Filing, Examination, Granting | 1663 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
16,578
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to blow-fill-seal (BFS) sealed single-dose containers comprising a pharmaceutical composition of an aqueous solution for use in oral administration, which composition comprises levothyroxine or liothyronine or a pharmaceutically acceptable salt thereof, preferably levothyroxine sodium, water and one or more co-solvents and is alcohol-free, exhibits a pH from 8,1 to 8,7, an average density from 1,18 to 1,23 grams per milliliter (g/ml), and viscosity from 20 to 60 cps.[French]
La présente invention concerne des récipients à dose unique scellés par formage-remplissage-scellage (BFS) comprenant une composition pharmaceutique d'une solution aqueuse destinée à être utilisée en administration orale, laquelle composition comprend de la lévothyroxine ou de la liothyronine ou un sel pharmaceutiquement acceptable de celles-ci, de préférence de la lévothyroxine sodique, de l'eau et un ou plusieurs co-solvants et est exempte d'alcool, présente un pH de 8,1 à 8,7, une densité moyenne de 1,18 à 1,23 gramme par millilitre (g/ml) et une viscosité de 20 à 60 cps.